Medicine, Antibiotics Exports Gaining Share In US, Italian Markets: Govt Data According To The Commerce Ministry Data, India

New Delhi: With the Union government focusing on boosting domestic manufacturing of pharmaceutical products, India’s medicine and antibiotics exports have started gaining significant market share in the US.

According to the commerce ministry data, India is the third largest import source of ‘medicine put up for retail sale’ for the US. The top two are Ireland and Switzerland.

In 2023, the country exported these medicines worth $9 billion as against $7.33 billion in 2022.

With this increase in the shipments, India’s share went up to 13.1 percent in 2023 from 10.08 percent in 2022. Share of the top exporter Ireland fell to 13.85 percent in 2023 from 17.18 percent in 2022 because its sales in the US went down to $9.5 billion in 2023 from $12.5 billion in 2022.

The second biggest exporter Switzerland also saw its share decline to 13.7 percent last year from 17.4 percent in 2022.

Similarly, India has increased its share among exporters of antibiotics in the Italian market. It is ranked 10th in that market by increasing its share to 2.12 percent in 2023 from 0.96 percent in 2022.

In value terms, the country’s antibiotics exports to Italy stood at $23.34 million in 2023 as against $11.48 million in 2022.

Further, the data showed that India’s competitiveness is growing in the Magnetic Resonance Imaging (MRI) apparatus market of Germany.

In 2023, the country made a small gain by increasing its export share in Germany to 1.7 percent from 0.45 per cent in 2022.

In value terms, India exported these MRI machines worth $13.02 million last year as against $2.93 million in 2022.

India is the sixth largest exporter of MRI apparatus, whereas the UK is the leader with exports of $460 million.

“Penetrating the EU market is difficult and it is important that we have a base coming in. These reflect some efforts which are being put in terms of monitoring various markets and various commodities to see where growth can be pushed,” an official said.

Pharma and medical devices manufacturing is the priority area for the government and these two sectors were the first ones to get a Production Linked Incentive (PLI) scheme.

Related Posts

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines